Table 1.

Patient characteristics. AF- atrial fibrillation; SVT- supraventricular tachycardia; VT- ventricular tachycardia.

	All Patients	Site 1	Site 2	Site 3	Site 4	Site 5
Thalassemia major	43	10	10	9	10	4
BThal/HbE	6	0	0	0	0	6
Male	17	3	4	2	5	3
Female	32	7	6	7	5	7
Age [years]	30.9 +/− 8.8	38.3 +/− 4.4	27.7 +/− 3.7	35.4 +/− 10.5	22.0 +/− 3.5	31.3 +/− 9.5
Mean Myocardial T2* +/− SD	24.9 +/− 14.9	24.5 +/− 12.5	13.7 +/− 6.4	34.2 +/− 12.9	25.0 +/− 19.1	28.2 +/− 15.1
Myocardial T2* range	2.7 – 52.9	4.9 – 40.9	8.0 – 29.1	17.4 – 52.9	2.7 – 51.1	6.7 – 52.3
Mean Liver T2* +/− SD	6.5 +/− 7.3	8.7 +/− 9.5	9.6 +/− 9.5	4.7 +/− 3.0	3.2 +/− 2.5	N/A
Liver T2* range	0.5 – 26.2	1.1 – 26.2	0.5 – 23.0	2.3 – 11.8	0.8 – 7.5	N/A
Time between scans [days]	20.1 +/− 19.0	12	2	56	26	8
History of heart Failure	1	0	0	0	0	1
History of arrhythmia	6	1 SVT	1 AF,1 VT	1 AF	1 AF	1 VT
History of coronary or valvular disease	0	0	0	0	0	0
Blood transfusions per year	29.2 +/− 11.9	34.4 +/− 7.2	29.8 +/− 12.8	33.0 +/− 4.0	35.1 +/− 9.1	14.2 +/− 10.6
Serum ferritin ug/L	2950 +/−3068	5025 +/− 3976	2369 +/− 2479	1705 +/− 1102	2799 +/− 2504	2728 +/− 3758
Deferoxamine	16	0	2	5	5	4
Deferiprone	4	1	0	2	1	0
Deferasirox	3	0	1	2	0	0
Deferoxamine + deferiprone	24	9	7	0	4	4
No Chelation	2	0	0	0	0	2
Cardiac Medication	6	2	2	0	1	1